Physician profile
Steven A Morris
NPI 1295763035
$986.94
in general payments reported to CMS, 2019-2025
14 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $38.20 · 2021: $12.83 · 2022: $125 · 2024: $103 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $429.79 | 2019-2025 | Krystexxa |
| Aurinia Pharma U.S., INC. | $124.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $72.80 | 2019 | |
| Akebia Therapeutics INC | $63.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $42.16 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $35.20 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $35.07 | 2019 | |
| Nxstage Medical, INC. | $33.71 | 2024 | |
| Mallinckrodt Enterprises LLC | $29.17 | 2019 | |
| Vifor Pharma, INC. | $26.18 | 2019-2021 | |
| Ardelyx, INC. | $25.76 | 2024 | Ibsrela |
| Cormedix INC. | $24.76 | 2024 | Defencath |
| Daiichi Sankyo INC. | $22.73 | 2019 | |
| Genzyme Corporation | $20.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.